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Abstract Objective Changes in bleeding patterns could influence the decisions of healthcare
professionals to change the levonorgestrel-releasing intrauterine system (LNG-IUS)
before 7 years of use, the recommended period of extended use.We evaluated changes
in the bleeding patterns of users of the 52mg LNG-IUS at the end of use of the first (IUS-
1) and during the second device (IUS-2) use.
Methods We performed an audit of the medical records of all women who used two
consecutive LNG-IUSs at the Family Planning clinic. We evaluated the
sociodemographic/gynecological variables, the length of use, and the bleeding
patterns reported in the reference periods of 90 days before removal of the IUS-1
and at the last return in use of IUS-2. We used the McNemar test to compare bleeding
patterns. Statistical significance was established at p<0.05.
Results We evaluated 301 women aged (mean SD) 32 (6.1) years, with lengths of
use of 68.9 (16.8) and 20.3 (16.7) months for the IUS-1 and IUS-2, respectively. No
pregnancies were reported. Bleeding patterns varied significantly among women who
used the IUS-2 for 7 months to 6 years when compared the bleeding patterns
reported in IUS-1 use. Eighty-nine out of 221 (40%) women maintained amenorrhea
and infrequent bleeding; 66 (30%) evolved to bleeding patterns with light flow, and 66
(30%) maintained or evolved to heavy flow patterns (p¼0.012). No differences were
observed among the 80 women with  6 months of use.
Conclusion Changes in bleeding patterns occur during the use of LNG-IUS and should
not be decisive for the early replacement of the device.
Resumo Objetivo Variações no padrão de sangramento podem afetar a decisão de troca do
sistema intrauterino de levonorgestrel (SIU-LNG) antes do período de uso estendido
recomendado de 7 anos. Nós avaliamos mudanças no padrão de sangramento de
usuárias ao final do uso do primeiro SIU-LNG 52mg (SIU-1) e durante o uso do segundo
dispositivo (SIU-2).
Métodos Revisamos os prontuários de todas as mulheres que inseriram consecutiva-
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The 52mg levonorgestrel-releasing intrauterine system
(LNG-IUS) is a long-acting, reversible contraceptive method,
also used as treatment forheavymenstrual bleeding.1,2 It has
been widely used with high satisfaction rates, and many
women opt for the insertion of a new IUS after the end of the
approved lifespan of 5 years.3,4 In addition, it has been
reported that this device could be used beyond the approved
5-year lifetime, and data have been published up to 7 years of
use, which improves cost-effectiveness.5–7 However, some
users and healthcare professionals (HCPs) associate changes
in bleeding patterns at the end of the approved lifespanwith
decreasing contraceptive efficacy of the method, which does
not seem supported by the medical literature.5–7
The high effectiveness of LNG-IUS is attributable to two
mechanisms of local action: the antiproliferative effect upon
the endometrium, which induces amenorrhea, and the effect
on cervical mucus, which impairs sperm penetration.8–10
The 52mg LNG-IUS releases 20 µg/day immediately after
device placement and declines over time to 10 to 12 µg/day
up to 5 years of use; however, LNG has been detected in the
8th year of use.11,12 The serum mean (SEM) LNG levels
decreased from 25327 pg/ml (range, 86–760) during the
first 2months after placement to 13712 (range, 23–393) at
7 years of use and 1199 pg/ml (range, 110–129) at 8 years
after placement.11 The reduction of LNG levels correlated to
increments of endometrial thickness (from 2.8 -0.1mm at
84 months of use to 3.8 -0.5mm at 102 months of use).11
The authors reported that as LNG decreased over time, the
amenorrhea rate decreased from41.8% at 84months to 31.5%
at 102 months of use, but no correlations were found
between serum LNG levels and bleeding patterns.11
Despite the lower release of LNG with over time use, the
described contraceptive failure is 0.2/100 women-years
(WY) and is similar to the rates reported for new LNG-IUSs
loaded with 19.5mg (Kyleena— Bayer PLC, Reading, Berk-
shire, UK), which release 16 µg/day and 7.4 µg/day of LNG
at the 1st and 5th year of use, respectively, and only slightly
less (0.4/100 WY) for the LNG-IUS loaded with 13.5mg
(Jaydess/Skyla – Bayer Canada, Toronto, ON, Canada), which
releases 12 µg/day and 5 µg/day at the end of the 1st and 3rd
year of use, respectively.13–15
Despite the large body of evidence concerning efficacy and
bleeding patterns among 52mg LNG-IUS users, information
about the use of 2nd or 3rd consecutive LNG-IUSs is
scarce.1,3,4,13,16,17 It is not well established whether users of
the LNG-IUSmaintain the same bleeding patterns observed at
the end of the 5-year approved lifespan after changing the
device out for a newone or if thebleeding patterns change to a
lighter orheavierflow. It is important toknow if changes in the
bleeding pattern still occurduring the predictedperiodof high
contraceptive efficacy of the method. This information may
help to dispel the idea that the changes in menstrual pattern
that take place in year 5 of using the method correspond to a
decrease in the contraceptive efficacy.
The objective of our study was to assess and compare self-
reported bleeding patterns of LNG-IUS users with reference
periods of 90 days before the removal of first IUS (IUS-1), after
theapproved lifespanandsame-dayreplacementwithasecond
IUS (IUS-2), and at the last annual return visit of IUS-2.
Methods
This was a retrospective cohort study conducted at the Family
Planning clinic, Department of Obstetrics and Gynecology, The
ethical committeeof the institutionapprovedthestudyprotocol
andauthorized thedatacollectionandanalysis; the information
was unidentifiable following collection. The medical records of
all women who received a 52mg LNG-IUS (Mirena—Bayer Oy,
Turku, Finland) for contraception at our service and consecu-
tively received an IUS-2 were included in the study. The data
were collected from information contained in the medical
records of the service. Women who did not have information
sociodemográficas/ginecológicas, o tempo de uso, e os padrões de sangramento
relatados nos períodos de referência de 90 dias antes da remoção do SIU-1 e no último
retorno em uso do SIU-2. Usamos o teste de McNemar para comparar os padrões de
sangramento. A significância estatística foi estabelecida em p<0,05.
Resultados Analisamos os dados de 301mulheres com idade (média desvio padrão
[DP]) de 32 (6,1) anos e tempo de uso de 68,9 (16,8) e 20,3 (16,7) meses para o
SIU-1 e SIU-2, respectivamente. Nenhuma gravidez foi relatada. Os padrões de
sangramento variaram significativamente durante o uso do SIU-2 (7 meses a 6
anos) em relação ao padrão relatado no SIU-1. Oitenta e nove das 221 (40%) mulheres
mantiveram amenorreia e sangramento infrequente; 66 (30%) evoluíram para padrões
de sangramento com fluxo leve e 66 (30%) mantiveram ou evoluíram para padrões de
fluxo intenso (p¼0,012). Não foram observadas diferenças entre as 80 mulheres que
utilizavam o SIU-2 há 6 meses.
Conclusão Mudanças nos padrões de sangramento ocorrem durante o uso do LNG-
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about bleeding patterns in the medical records were not
included. We obtained sociodemographic and obstetrics infor-
mation, total length of use, bleeding patterns and rates and
reasons fordiscontinuationof the IUS-2.Theprofessionalsofour
service followed an interview script about the women’s men-
strual history at the time of insertion of the IUS, and thewomen
are questioned about the menstrual bleeding presented in the
last 90 days on subsequent return visits. Theywere categorized
into 5 patterns: amenorrhea (no bleeding), infrequent bleeding
(1–2 episodes of bleeding and/or spotting), frequent bleeding
(>5episodesofbleedingand/or spotting), regularbleeding (3–5
episodes of bleeding and/or spotting), and prolonged bleeding
(> 14 consecutivedays of bleeding and spotting).18 For this
study, we collected information on bleeding patterns self-
reported by women in a reference period of the last 90 days
before IUS-1 removal and 90 days before the last return visit to
the clinic when using IUS-2. The patterns of “frequent” and
“prolonged” bleeding were computed together for analysis as
“frequent/prolonged” bleeding due to the scarce number of
women with these patterns.
Statistical Analysis
We used the χ2, Fisher exact, Mann-Whitney, and Kruskal-
Wallis tests followed by a post-hoc Dunn test to identify the
variables with association. For comparisons between bleed-
ing patterns, we used the McNemar test. Statistical signifi-
cance level was established at p<0.05. The Statistical
Analysis System (SAS) software program, version 9.4 (SAS
Institute Inc., Cary, NC, USA) was used for the analysis.
Results
Between 2007 and 2017, 12,570 LNG-IUSs were inserted at
our service. We reviewed the medical charts of 316 women
who received a 2nd consecutive LNG-IUS on the sameday as
the removal of the 1st one at the end of the approved lifespan.
From those women, 15 were excluded due to lack of reliable
information; consequently, we report information regarding
301 women with information about bleeding patterns. The
mean (standard error of the mean [SEM]) age at IUS-1 and
IUS-2 insertion was 32.0 (0.35) and 37.7 (0.37), respec-
tively. The length of use of IUS-1 and IUS-2 was 68.9 (0.97)
and 20.3 (0.96) months, respectively. Most of the women
attended  8years of schooling and were living with a
partner (►Table 1).
We also observed that at the end of use of the IUS-1,
43.8%, 23.9%, 24.9%, and 7.3% of women had reported
amenorrhea, infrequent, regular, and frequent/prolonged
bleeding, respectively (►Table 2). The length of use of the
IUS-1 was different according to the bleeding pattern and
was longer among womenwith amenorrhea compared with
those with regular or frequent/prolonged bleeding; it was
also longer among women with infrequent compared with
those with frequent/prolonged bleeding (►Table 2). Addi-
tionally, the length of use (IUS-1þ IUS-2) was significantly
higher among women with amenorrhea compared with
women with frequent/prolonged bleeding or regular bleed-
ing (►Table 2).
At the last visit using the IUS-2, we observed an increment
of users with amenorrhea (50.8%) and infrequent bleeding
(28.5%), and a low proportion of womenwith regular (15.6%)
or frequent/prolonged bleeding (4.9%) (►Table 3).
►Table 4 shows the comparison between the frequencies
of bleeding patterns presented at the end of use of the IUS-1
and at the last visit using the IUS-2. Of the 221 women who
used the IUS-2 from 7months to 6 years, only 89/221women
(40%) maintained the same patterns of amenorrhea and
infrequent bleeding; 66 (30%) evolved to bleeding patterns
with lighter flow, and 66 (30%) maintained or evolved to
patterns with heavier flow than presented when in use of
IUS-1 (p¼0.012). Among the 104 women with amenorrhea
at the end of IUS-1 use, only 70 continued to experience
amenorrhea (►Table 4).
Of the 80 women who used the IUS-2 for only 6 months,
there were no differences when comparing the bleeding
patterns with those observed at the end of use of the IUS-1
(p¼0.1163). At the end of the data collection (September/
2017), 277 (92%)womenwere still using the device and9were
usinga3rd LNG-IUSafter theendof the approved lifespan.Also,
24 women had the device removed: 3 wished to become
pregnant, 9 reached menopause, and 12 had expulsions.
Discussion
Our results showed that women using a 52mg LNG-IUS had
significantly varied bleeding patterns over time while using
thismethod.We emphasize that womenwith amenorrhea at
the end of use of the IUS-1 also changed to other bleeding
patterns like infrequent (24%), and even regular and
Table 1 Characteristics of users of a second consecutive
levonogestrel-releasing intrauterine system
Variables n¼ 301 (100%)
n (%)
Age at IUS-1 placement, mean (SEM) 32.0 (0.35)
Age at IUS-2 placement, mean (SEM) 37.7 (0.37)
Schooling (years), n (%)
 8 243 (82.6)
> 8 51 (17.1)
Marital status, n (%)
With a partner 246 (82.8)
Without a partner 51 (17.1)
Number of pregnancies, mean (SD) 1.7 (0.9)
Number of deliveries, mean (SD) 1.5 (0.8)
Length of use of the IUS-1 (months),
mean (SEM)
68.9 (0.97)
Length of use of the IUS-2 (months),
mean (SEM)
20.3 (0.96)
Abbreviations: IUS, intrauterine system; SD, standard deviation; SEM,
standard error of the mean.
Missing¼ 2 (299 women evaluated); Missing¼ 7 (294 women eval-
uated); Missing¼ 4 (297 women evaluated).
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frequent/prolonged bleeding (8.6%), during the use of the
IUS-2.
Our findings are important to HCPs to determine how to
counsel women on when to change the LNG-IUS and to
consider the possibility of extended use for 7 years and
beyond.5,7 In our service, some HCPs have expressed con-
cerns of reduced contraceptive effectiveness when women
keep the same device beyond the manufacturer-recom-
mended 5years, mainly among women who reported
changes in their bleeding patterns and especially if they
experienced amenorrhea at any time during use and changed
to other bleeding patterns after 5 years of use. The behavior
of the HCPs for early removal and replacement of the IUSwas
reflected in the results presented in this report showing long
periods of use for women with amenorrhea and short
periods among women with other bleeding patterns.
Because no correlation was reported between serum LNG
concentrations and bleeding patterns, we can speculate that
low doses of LNG after the 5th year of use of the 52mg LNG-
IUS maintain the high contraceptive efficacy independently
of the observed bleeding patterns, which were observed
previously.6,7,11,12,19
We found at end use of IUS-1 that amenorrhea was
observed in 43.8% of users; this result is in agreement
with a recent prospective study that described 41.8% of
amenorrhea at 5 years of use of the LNG-IUS.13
Our results showed that women with amenorrhea dis-
played infrequent and regular bleeding patterns in the 2


















Age at IUS-1, mean (SD)¶ 31.8 (6.1) 32.3 (6.0) 32.0 (6.0) 33.1 (7.7) 0.742
Age at IUS-2, mean (SD)¥ 37.9 (6.2) 37.8 (6.4) 37.1 (6.6) 38.3 (8.4) 0.758
Number of pregnancies, mean (SD) 1.7 (0.9) 1.9 (0.8) 1.8 (0.9) 1.6 (1.4) 0.082
Number of deliveries, mean (SD) 1.5 (0.7) 1.7 (0.7) 1.6 (0.8) 1.4 (0.9) 0.183
Number of abortions, mean (SD) 0.1 (0.5) 0.1 (0.4) 0.3 (0.7) 0.1 (0.6) 0.362
Length of use of IUS-1, months, mean (SD) 73.0 (10.4) 68.7 (17.4) 63.8 (22.4) 63.1 (18.3) 0.0002#
Length of use of IUS-2, months, mean (SD) 21.9 (16.8) 16.6 (15.6) 20.0 (18.2) 23.5 (13.4) 0.055
Total length of use months, mean (SD) 95.4 (21.0) 85.4 (18.2) 84.3 (21.7) 86.5 (23.6) 0.0006&
Abbreviation: IUS-1, first intrauterine system; ISU-2, second intrauterine system; SD, standard deviation.
¶Age at first placement; ¥Age at second placement; Kruskal Wallis test; #Post-hoc Dunn test – amenorrhea> frequent/prolonged and
amenorrhea> regular; spotting> frequent/prolonged; &Post-hoc Dunn test – amenorrhea> frequent/prolonged and amenorrhea> regular;
Missing¼ 1 (71 women evaluated); Missing¼ 1 (74 women evaluated).
Table 3 Distribution of women according to bleeding patterns
reportedduring the last90daysofuseof the1st intrauterine system

















Amenorrhea 132 (43.8) 35 (43.7) 118 (53.4)
Infrequent 72 (23.9) 24 (30.0) 62 (28.0)
Regular 75 (24.9) 17 (21.2) 30 (13.5)
Frequent/
prolonged
22 (7.3) 4 (5.0) 11 (4.9)
Abbreviation: IUS, intrauterine system.
Table 4 Bleeding pattern variations during the last 90 days before removal of the 1st intrauterine system and 90 days before last
visit using the 2nd intrauterine system for> 7 months to 6 years














Amenorrhea, n¼104 70 (59.3) 25 (40.3) 3 (10.0) 6 (54.5) 0.012
Infrequent, n¼48 23 (19.5) 19 (30.6) 5 (16.6) 1 (9.0)
Regular, n¼ 50 16 (13.5) 14 (22.5) 18 (60.0) 2 (18.1)
Frequent/prolonged, n¼ 19 9 (7.6) 4 (6.4) 4 (13.3) 2 (18.1)
@McNemar test. Excludes the 80 women with length of use of the IUS-2  6 months.
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study periods within the range described in previous pro-
spective studies with slight variations, possibly due to the
retrospective characteristic of our study.4,16,17 A Sweden-
based study followed 82 women who underwent a 2nd
consecutive IUS placement after 7 years of use with the 1st
one, and the authors reported that 26% and 60% of partic-
ipants experienced amenorrhea in the 1st period for the 1st
IUS and for the last 5 years of use for the 2nd device,
respectively, while showing 70% and 28% with
regular/scanty bleeding patterns while using the 1st and
2nd IUSs, respectively.4
In addition, a multicenter study of 204 women with a
15-month follow-up evaluated bleeding patterns during
the 1st LNG-IUS (between 4.3 and 4.9 years) and showed a
mean of 7 and 8 days of bleeding/spotting at 90 days before
and after changing the device, respectively, decreasing to
4 days after 1 year of use with the 2nd IUS.16 Of the 204
women in that study, 170 women remained at follow-up,
and the bleeding patterns described in the last 90 days 2 to
5 years after placement of the 2nd IUS showed reductions of
bleeding in 70% of the women, while>49% of women
experienced amenorrhea, which was associated with high
rates of satisfaction and continuation.17 The results of our
study were similar to those found in these prospective
studies.4,16,17
The main limitation of the present study was the retro-
spective design, which could introduce bias. On the other
hand, themain strength is that we evaluated the same cohort
of women at two different moments, which may have
contributed, at least in part, to the quality of the evaluation
of the variations between bleeding patterns. Additionally,
another strength is that we assessed the bleeding patterns
90 days before the last annual consultation of the IUS-2,
which occurred between 7 months and 6years after
placement.
Our study has two major implications for HCPs who
provide care in family planning. First, the bleeding patterns
observed in LNG-IUS users did not change in the first
6 months after changing the device for a new one. Second,
in the period from 7months up to 6 years after the 2nd device
placement, it is expected that the bleeding patterns will vary
from the pattern observed when removing the 1st IUS. This
information may help users and HCPs to more readily accept
the extended use of the method and prevent both from
interpreting changes in bleeding patterns as decreasing the
efficacy of the method.
Although users of a second LNG-IUS reported high rates
of amenorrhea and infrequent bleeding and lower rates of
regular, frequent/prolonged bleeding after changing
the LNG-IUS, some women also experienced bleeding
pattern changes from light flow to frequent/prolonged
flow, which has not been found to be linked to contracep-
tive efficacy.
As we evaluated the time of IUS-2 use for up to 6 years of
use, a period in which its efficacy is still high, these changes
in bleeding pattern did not appear to indicate a decrease in
the contraceptive efficacy of the method. In addition, we did
not have any pregnancy in the period of IUS-2 use.
Conclusion
Changes in bleeding patterns occur during the use of LNG-
IUS and should not be decisive for the early replacement of
the device.
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